Esanex raises $500,000 from BioCrossroads

Cancer company Esanex Inc. (Indianapolis, Ind.) raised $500,000 from BioCrossroads Indiana Seed Fund II. The funding is part of Esanex's series A round; according to a December SEC filing, the newco has raised $15.5 million in a venture round from investors that include Intersouth Partners and Lilly Ventures. Esanex's SNX-5422, an oral heat shock protein 90 (Hsp90) inhibitor, is in a Phase I trial to treat solid tumors. ...